RxDoctor Payments Data

Marna Taylor

Family · Berkley, MINPI 1861975856

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $18,654 of the $25,318 with a category attached, or 73.7%. 28 manufacturers reported payments, led by Viiv Healthcare Company at 37.0% of the total. Reporting peaked in 2023 at $9,448 and has fallen 74.0% since, to $2,454 in 2025. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,318in general payments, 2019–2025

Across 824 payments — averaging $30.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$9K
  • Gilead$9K
  • AbbVie$1K
  • Merck$871
  • Johnson & Johnson$779
  • Janssen Products, LP$672
  • plus $4K from 22 others

What the payments were for

  • Consulting fees$4,14516%
  • Travel & lodging$2,3269%
  • Food & beverage$18,65474%
  • Education$1941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,318 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala40$158,097
PrezcobixDarunavir/Cobicistat19$46,049
TivicayDolutegravir Sodium19$42,207
DescovyEmtricitabine/Tenofov Alafenam16$31,462
OzempicSemaglutide31$29,800
FarxigaDapagliflozin Propanediol31$21,547
MounjaroTirzepatide13$15,400
JardianceEmpagliflozin19$15,369
Lamivudine12$2,695
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,261
Atorvastatin Calcium63$351
Fluticasone Propionate14$157
Levothyroxine Sodium15$156
Omeprazole23$155
Lisinopril46$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$8,851$189,55956 claims
Johnson & JohnsonPrezcobix$779$46,04919 claims
Viiv Healthcare CompanyTivicay$9,376$42,20719 claims
Novo NordiskOzempic$74$29,80031 claims
AstraZenecaFarxiga$269$21,54731 claims
Lilly USA, LLCMounjaro$581$15,40013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Berkley

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →